MarketCapExport financials
Ironwood Pharmaceuticals (IRWD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Ironwood Pharmaceuticals Income Statement 2025-2008 | IRWD
Brief overview of financial results at Ironwood Pharmaceuticals
The overview follows changes across a five-year period. Revenue reported by Ironwood Pharmaceuticals was $390 million at the beginning of the period and $47.7 million at the end. The five-year change reached −87.8%, while CAGR stood at −34.3%. The decline points to a contraction in the scale of the business.
The five-year EBITDA result moved by −31.4%: from $145 million to $99.6 million. EBITDA grew faster than revenue, indicating positive operating leverage. Comparing the endpoints gives EBITDA margins of 37.3% and 208.8%. The business generated more EBITDA from each unit of revenue.
Net income changed from 106 million dollars to 24 million dollars (−77.4%). Net income grew faster than revenue, indicating improved overall efficiency.
The five-year change in capitalization reached −93.8%: from $1.6 billion to $100 million. The negative valuation trend points to increased investor caution.
Summary assessment
The indicators point to a weaker financial profile. Key strengths include positive operating leverage. The overall view is constrained by a weaker market valuation, lower net income and limited revenue growth. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Ironwood Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
100 M | 234 M | 2.28 B | 1.76 B | 1.81 B | 1.63 B | 1.87 B | 1.7 B | 1.93 B | 1.71 B | 1.1 B | 1.79 B | 1.4 B | 1.15 B | 1.24 B | 843 M | - | - |
Shares |
162 M | 159 M | 155 M | 154 M | 162 M | 159 M | 154 M | 153 M | 149 M | 146 M | 142 M | 137 M | 116 M | 106 M | 99.9 M | 89.7 M | 7.12 M | - |
Historical Prices |
0.62 | 1.47 | 14.7 | 11.4 | 11.2 | 10.2 | 12.1 | 11.4 | 12.4 | 12 | 7.73 | 13 | 11.6 | 10.7 | 12.5 | 9.41 | - | - |
Net Income |
24 M | 880 K | -1.03 B | 175 M | 528 M | 106 M | 21.5 M | -282 M | -117 M | -81.7 M | -143 M | -190 M | -273 M | -72.6 M | -64.9 M | -51.9 M | -73.3 M | - |
Revenue |
47.7 M | 90.5 M | 118 M | 411 M | 414 M | 390 M | 428 M | 347 M | 298 M | 274 M | 150 M | 76.4 M | 22.9 M | 150 M | 65.9 M | 43.9 M | 34.3 M | - |
Cost of Revenue |
- | - | - | - | - | 3.14 M | 23.9 M | 32.8 M | 19.1 M | 1.87 M | 12 K | 25.6 M | 7.2 M | 965 K | - | - | - | - |
Gross Profit |
- | - | - | - | - | 386 M | 405 M | 314 M | 279 M | 272 M | 150 M | 50.9 M | 15.7 M | 149 M | 65.9 M | - | - | - |
Operating Income |
98.5 M | 93.1 M | -945 M | 250 M | 232 M | 143 M | 120 M | -151 M | -15.4 M | -51.9 M | -102 M | -169 M | -252 M | -72.8 M | -66.1 M | -60.8 M | -60.8 M | - |
Interest Expense |
193 K | 640 K | 21.6 M | 7.6 M | 31.2 M | 29.5 M | 36.6 M | 37.7 M | 36.4 M | 39.2 M | 31.1 M | 21.2 M | 21 M | 59 K | 63 K | 196 K | 318 K | - |
EBITDA |
99.6 M | 94.3 M | -944 M | 252 M | 234 M | 145 M | 123 M | -93.9 M | -102 M | -40.7 M | -72.8 M | -157 M | -240 M | -61.4 M | -56.1 M | -54.6 M | -56.1 M | - |
Operating Expenses |
- | - | - | - | - | 243 M | 287 M | 416 M | 388 M | 314 M | 234 M | 220 M | 268 M | 222 M | 132 M | 29.6 M | 95.1 M | - |
General and Administrative Expenses |
82.3 M | 144 M | 158 M | 116 M | 111 M | 140 M | 172 M | 241 M | 233 M | 173 M | 125 M | 118 M | 123 M | 92.5 M | 45.9 M | 27.2 M | 19 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Ironwood Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
165 M | 164 M | 163 M | 200 M | 162 M | 162 M | 161 M | 273 K | 160 M | 159 M | 158 M | 195 M | 156 M | 155 M | 154 M | 154 M | 153 M | 153 M | 158 M | 162 M | 163 M | 162 M | 161 M | 216 M | 160 M | 159 M | 158 M | 156 M | 156 M | 156 M | 155 M | 154 M | 153 M | 152 M | 151 M | 149 M | 150 M | 149 M | 148 M | - | 145 K | 145 K | 144 K | - | 142 K | 142 M | 141 M | 1.01 M | 139 M | 138 M | 130 M | 116 M | 121 M | 113 M | 108 M | - | 107 M | 107 M | 104 M | - | 100 M | 99.7 M | 99.1 M |
Net Income |
59.8 M | 51.3 M | 40.8 M | -2.28 M | 40.1 M | 23.6 M | -37.4 M | 2.26 M | 3.65 M | -860 K | -4.16 M | -1.74 M | 15.3 M | -1.09 B | 45.7 M | 48.9 M | 50.3 M | 37.1 M | 38.8 M | 41.4 M | 55.8 M | 391 M | 39.9 M | 43.2 M | 34.4 M | 25.2 M | 3.34 M | 47.9 M | 20.6 M | 12.3 M | -59.3 M | -15.5 M | -174 M | -49.4 M | -43.1 M | 12.1 M | -32.3 M | -44.2 M | -52.5 M | -13.5 M | -33.2 M | -21.7 M | -13.3 M | -14 M | -47.4 M | -48 M | -33.2 M | -37.6 M | -42 M | -60.4 M | -49.6 M | -52 M | -61.8 M | -65.1 M | -93.9 M | -43.9 M | 47.6 M | -40.8 M | -35.6 M | -6.97 M | -20.6 M | -18.8 M | -18.4 M |
Revenue |
133 M | 113 M | 107 M | 47.7 M | 122 M | 85.2 M | 41.1 M | 90.5 M | 91.6 M | 94.4 M | 74.9 M | 118 M | 114 M | 107 M | 104 M | 107 M | 109 M | 97.2 M | 97.5 M | 117 M | 104 M | 104 M | 88.8 M | 117 M | 103 M | 89.4 M | 79.9 M | 126 M | 131 M | 102 M | 68.7 M | 131 M | 65.7 M | 81.1 M | 69.2 M | 94.2 M | 86.8 M | 65.1 M | 52.2 M | 87.5 M | 66.1 M | 54.4 M | 66 M | 53.3 M | 39.6 M | 27.7 M | 28.9 M | 38.1 M | 16.9 M | 6.84 M | 14.6 M | 5.03 M | 4.93 M | 9.66 M | 3.26 M | 27 M | 96.4 M | 14.6 M | 12.2 M | 32.2 M | 12.2 M | 11.3 M | 10.2 M |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 897 K | 2.24 M | 2.24 M | 2.24 M | 11 M | 506 K | 11.3 M | 1.04 M | - | 4.62 M | 4.06 M | 2.61 M | 8.98 M | 6.08 M | 3.5 M | 531 K | - | - | - | - | - | - | 8.15 M | 12 K | 1.74 M | -8.89 M | 10.5 M | 1.92 M | 533 K | 2.02 M | 3.42 M | 1.23 M | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 116 M | 101 M | 87.2 M | 77.7 M | 115 M | 131 M | 90.9 M | 67.7 M | - | 61.1 M | 77 M | 66.5 M | 85.2 M | 80.7 M | 61.6 M | 51.6 M | - | - | - | - | - | - | 19.6 M | 28.9 M | 36.3 M | 25.8 M | -3.68 M | 12.7 M | 4.5 M | 2.91 M | 6.24 M | 2.02 M | - | - | - | - | - | - | - | - |
Operating Income |
93.1 M | 79.3 M | 72.6 M | 6.8 M | 75.5 M | 45.3 M | -29.1 M | 31.5 M | 25.6 M | 25 M | 11 M | 37.6 M | 40 M | -1.08 B | 60.1 M | - | 68.5 M | 55.7 M | 57.8 M | - | 65.2 M | 65.1 M | 45.4 M | 51.4 M | 45.6 M | 32.7 M | 13.2 M | 49.6 M | 65.9 M | 21.6 M | -16.9 M | - | -147 M | -14.7 M | -35.9 M | 84.8 M | -19.4 M | -41 M | -39.7 M | - | -28.3 M | -15.3 M | -1.97 M | - | -26.2 M | -42 M | -28.1 M | -33.1 M | -36.7 M | -55.1 M | -44.4 M | -46.7 M | -56.6 M | -59.9 M | -88.8 M | - | 47.6 M | -40.8 M | -35.6 M | - | -21.6 M | -19 M | -18.5 M |
Interest Expense |
41 K | 42 K | 42 K | 77 K | 40 K | 39 K | 37 K | - | - | - | 7.23 M | 8.42 M | 9.84 M | 1.84 M | 1.53 M | - | 1.52 M | 2.21 M | 2.34 M | - | 7.84 M | 7.73 M | 7.63 M | 7.52 M | 7.42 M | 7.32 M | 7.22 M | 7.12 M | 10.5 M | 9.43 M | 9.59 M | - | 9.48 M | 9.38 M | 9.27 M | 9.21 M | 9.14 M | 9.05 M | 8.98 M | - | 9.76 M | 9.83 M | 9.91 M | - | 10 M | 5.87 M | 5.22 M | 5.26 M | 5.32 M | 5.3 M | 5.28 M | 5.3 M | 5.26 M | 5.32 M | 5.12 M | - | 14 K | 13 K | 14 K | - | 16 K | 17 K | 16 K |
EBITDA |
93.1 M | 80.2 M | 73 M | 7.26 M | 76 M | 45.3 M | -28.6 M | 32 M | 26.1 M | 25 M | 11.5 M | 38.1 M | 40.5 M | -1.08 B | 60.4 M | - | 69.6 M | 55.7 M | 58.2 M | - | 66.3 M | 65.1 M | 45.8 M | 51.8 M | 47.4 M | 33.4 M | 13.9 M | 50.5 M | 69.1 M | 22.4 M | -16.2 M | - | -145 M | -11.2 M | -32.4 M | 88.3 M | -17.5 M | -40.6 M | -39.3 M | 3.3 M | -20.8 M | -10 M | 865 K | - | -17.4 M | -38.9 M | -25.2 M | -30.2 M | -33.6 M | -52.1 M | -41.2 M | -43.7 M | -53.5 M | -57.1 M | -86 M | - | 56.1 M | -35.3 M | -33 M | - | -14.3 M | -13.9 M | -16.4 M |
Operating Expenses |
- | -79.3 M | - | - | -75.5 M | -45.3 M | - | -31.5 M | -25.6 M | -25 M | - | -37.6 M | -40 M | 1.08 B | 44 M | - | 40.2 M | - | 39.7 M | - | 38.6 M | 38.9 M | 43.4 M | 64.4 M | 55.6 M | 54.5 M | 64.5 M | 65.7 M | 64.8 M | 69.3 M | 84.6 M | - | 208 M | 91.7 M | 102 M | 437 K | 100 M | 103 M | 91.3 M | - | - | - | - | - | - | 61.6 M | 57 M | 69.5 M | 62.6 M | 51.4 M | 57.1 M | 51.2 M | 59.5 M | 66.1 M | 90.9 M | - | 48.8 M | 55.4 M | 47.9 M | 39.2 M | 33.8 M | 30.2 M | 28.8 M |
General and Administrative Expenses |
11.6 M | 11.3 M | 12 M | 19.3 M | 21.9 M | 16.8 M | 24.3 M | 33.6 M | 36.1 M | 37 M | 37.6 M | 38.7 M | 36 M | 52.5 M | 31.1 M | - | 28.6 M | 30.1 M | 28.9 M | - | 27.7 M | 27.1 M | 27.7 M | 34 M | 34.9 M | 34.6 M | 36.4 M | 39.2 M | 40.9 M | 43.2 M | 49.1 M | - | 50.5 M | 59.8 M | 59.5 M | 56 M | 61.8 M | 57.8 M | 55.6 M | - | 45 M | 36.9 M | 36.2 M | - | 30.4 M | 33 M | 30.3 M | 30.6 M | 28.5 M | 29.3 M | 29.9 M | 28.7 M | 30.3 M | 30.9 M | 33.4 M | - | 25.4 M | 23.2 M | 18.4 M | - | 10.9 M | 10.8 M | 9.22 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Ironwood Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Russia
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
